^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Soft Tissue Sarcoma
    Drug:pazopanib (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    VOTRIENT is a kinase inhibitor indicated for the treatment of adults with:...advanced soft tissue sarcoma (STS) who have received prior chemotherapy.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    03/29/2022
    Excerpt:
    Soft Tissue Sarcoma...Other Recommended Regimens...Gemcitabine and pazopanib
    Secondary therapy:
    gemcitabine
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    10/30/2020
    Excerpt:
    Soft Tissue Sarcoma: Preferred regimens…Pazopanib...
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

    Excerpt:
    Summary of recommendations...Pazopanib is an option in non-adipogenic STS [I, B].
    DOI:
    10.1093/annonc/mdy310